Summary of Use during Lactation

No information is available on the use of dactinomycin during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during dactinomycin therapy and for 14 days after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Dactinomycin

CAS Registry Number

50-76-0

Drug Class

• Breast Feeding
• Lactation
• Antineoplastic Agents
• Antibiotics, Antineoplastic
• Protein Synthesis Inhibitors
• Nucleic Acid Synthesis Inhibitors